Joining Hands with Hotgen India: Strengthening the Frontline Against Nipah Virus with Precision Diagnostic Tools

Recently, West Bengal, India, has once again raised the alarm over a Nipah virus outbreak. This highly fatal zoonotic virus has quickly attracted global attention. As of now, at least five confirmed cases have been reported, several healthcare workers have unfortunately been infected, and nearly one hundred people have been placed under home quarantine. Neighboring countries, including Thailand and Nepal, have also taken urgent measures to strengthen border quarantine and screening, aiming to prevent cross-border transmission of the virus.

With over twenty years of experience in the biopharmaceutical field, Hotgen Biotech possesses comprehensive strengths accumulated over the years in detecting pathogens of major infectious diseases, biological emergency response, and international services. The company is well-positioned to provide robust technical support and service assurance for epidemic prevention and control.

Accurate Detection, Rapidly Tracking the Virus

The Hotgen Nipah Virus Nucleic Acid Detection Kit (PCR–Fluorescent Probe Method) offers exceptionally high sensitivity and specificity. The kit can deliver results in a short time, significantly reducing the testing cycle and providing valuable time for timely prevention and control measures. Whether for epidemic monitoring and early warning by public health authorities, screening and quarantine of incoming travelers at customs, or diagnostic confirmation of suspected cases in hospitals, the Hotgen kit provides rapid and reliable testing support, enabling efficient epidemic prevention and control efforts.

Different epidemic prevention and control scenarios place varying demands on diagnostic kits. The Hotgen Nipah Virus Nucleic Acid Detection Kit is thoughtfully designed with excellent versatility and adaptability, compatible with a wide range of commonly used real-time PCR platforms. Whether it is large-scale laboratory equipment or portable on-site testing instruments, the kit can be easily deployed to meet diverse testing needs.

Up-converting Phosphor Technology Immunoassay Analyzer Listed in the Port Hazardous Biological Factor Monitoring Equipment

Focusing on emerging infectious diseases and biosafety needs, Hotgen Biotech has been continuously advancing the development of emergency testing technologies and application systems. The company has been recognized as the “Beijing Key Laboratory for Biological Emergency and Clinical POCT”, with a systematic layout covering key stages from pathogen detection technology R&D to emergency scenario applications, building strong capabilities for translating technologies to meet public health demands.

In 2023, the project “Construction of an Industry-Academia-Research-Application System for Novel Pathogen Detection Technologies and Pathogenic Mechanism Studies of Major Infectious Diseases”, jointly proposed by the Military Medical Research Institute of the Academy of Military Sciences of the Chinese PLA, Beijing Hotgen Biotech Co.,Ltd, and Beijing Sungen Biomedical Technology Co., Ltd., was awarded the First Prize of the Beijing Science and Technology Progress Award. This achievement marks authoritative recognition of the company’s collaborative research capabilities and technology translation level in the field of major infectious disease detection.

In the fields of biosafety and border control, the Up-converting Phosphor Technology Immunoassay Analyzer developed by Hotgen Biotech has been included in the “Technical Requirements for Equipment Configuration for Monitoring Hazardous Biological Factors at Ports”. It plays a key role in port quarantine and hazardous biological factor monitoring, providing reliable technical support for the early detection and warning of cross-border transmission risks, and effectively enhancing national biosafety monitoring capabilities. The accumulated expertise from this technology also offers a dependable approach for on-site rapid screening of pathogens such as the Nipah virus.

In terms of international presence, Hotgen Biotech has established a subsidiary in India, supported by a localized sales and after-sales service team. This enables rapid coordination of product delivery, technical support, and service response, providing a practical and effective on-the-ground solution for addressing local public health emergencies.

Facing global public health challenges, Hotgen Biotech will continue to leverage its integrated industry–academia–research–application innovation system to promote deep integration of scientific research and industrial applications. In response to emerging infectious disease risks such as the Nipah virus, the company will continue to capitalize on its strengths in major infectious disease detection, biological emergency system construction, and global service networks, working hand in hand with partners to reinforce the frontlines of public health security.